Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Depreciation and Depletion: 2015-2017

Historic Depreciation and Depletion for Intellia Therapeutics (NTLA) over the last 2 years, with Mar 2017 value amounting to $660,000.

  • Intellia Therapeutics' Depreciation and Depletion rose 252.94% to $660,000 in Q1 2017 from the same period last year, while for Mar 2017 it was $1.6 million, marking a year-over-year increase of 246.48%. This contributed to the annual value of $3.0 million for FY2017, which is 172.73% up from last year.
  • Latest data reveals that Intellia Therapeutics reported Depreciation and Depletion of $660,000 as of Q1 2017, which was up 64.59% from $401,000 recorded in Q4 2016.
  • In the past 5 years, Intellia Therapeutics' Depreciation and Depletion ranged from a high of $660,000 in Q1 2017 and a low of $33,000 during Q1 2015.
  • For the 3-year period, Intellia Therapeutics' Depreciation and Depletion averaged around $228,889, with its median value being $187,000 (2016).
  • Data for Intellia Therapeutics' Depreciation and Depletion shows a peak YoY spiked of 466.67% (in 2016) over the last 5 years.
  • Quarterly analysis of 3 years shows Intellia Therapeutics' Depreciation and Depletion stood at $104,000 in 2015, then surged by 285.58% to $401,000 in 2016, then surged by 252.94% to $660,000 in 2017.
  • Its last three reported values are $660,000 in Q1 2017, $401,000 for Q4 2016, and $265,000 during Q3 2016.